Larotrectinib, as a broad-spectrum anti-cancer targeted drug with NTRK gene fusion positivity, has been clinically studied to have significant therapeutic effects on various solid tumors, with an objective remission rate of over 75%, and can effectively penetrate the blood-brain barrier to control central nervous system metastases.

1 Clinical efficacy data

(1) In adult and pediatric NTRK gene fusion positive solid tumor patients, the objective response rate (ORR) of larotinib is 75%, with a complete response rate of 22%.

(2) The median progression free survival (PFS) was 28.3 months and the median overall survival (OS) was 44.4 months, significantly better than traditional chemotherapy regimens.

2 Tumor type response

(1) It has shown therapeutic effects on 17 types of tumors, including lung cancer, thyroid cancer, and sarcoma, with a response rate of up to 100% for salivary gland cancer.

(2) The remission rate for common childhood tumors such as infantile fibrosarcoma is 93%, and the adverse reactions are milder than chemotherapy.

3 Special Advantages

(1) As a TRK inhibitor, it can effectively penetrate the blood-brain barrier and achieve a control rate of 75% for brain metastases.

(2) The treatment response is rapid, with a median onset time of only 1.8 months, and the efficacy is long-lasting, with a median remission duration of 35.2 months.

4 Precautions for use

(1) It is necessary to confirm the NTRK gene fusion status through genetic testing such as NGS, as false negatives may affect the efficacy evaluation.

(2) Common adverse reactions include dizziness, fatigue, etc., most of which are grade 1-2 and can be managed through dose adjustment.